Xorte logo

News Markets Groups

USA | Europe | Asia | World| Stocks | Commodities



Add a new RSS channel

 
 


Keywords

2024-09-18 20:23:43| Engadget

Neuralink says the Food and Drug Administration has designated its experimental Blindsight implant as a "breakthrough device." The company is developing the technology in an attempt to restore blind people's sight. Manufacturers who apply to the FDA's voluntary breakthrough devices program and receive the designation from the agency are granted "an opportunity to interact with FDA experts through several different program options to efficiently address topics as they arise during the premarket review phase. The FDA also prioritizes breakthrough devices for review. Ultimately, a breakthrough device designation can accelerate development of a technology. Last year, the FDA gave the designation to 145 medical devices. Blindsight is separate from Telepathy, its implant that enables patients with spinal cord injuries to control computers using their thoughts, allowing them to play video games and design 3D objects. Neuralink owner and founder Elon Musk said in August that the company had implanted the chip into a second human patient Musk claimed back in March that Blindsight "is already working in monkeys. Resolution will be low at first, like early Nintendo graphics, but ultimately may exceed normal human vision." (Federal investigators have reportedly looked into Neuralink's animal testing practices but Musk said in March that "no monkey has died or been seriously injured by a Neuralink device.") The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see.Provided the visual cortex is intact, it will even enable those who have been blind from birth to see for the first time.To set expectations correctly, the vision https://t.co/MYLHNcPrw6 pic.twitter.com/RAenDpd3fx Elon Musk (@elonmusk) September 17, 2024 Blindsight "will enable even those who have lost both eyes and their optic nerve to see," Musk said following the FDA's designation. "Provided the visual cortex is intact, it will even enable those who have been blind from birth to see for the first time." He added that while the resolution of Blindsight is low to begin with, "eventually it has the potential [to] be better than natural vision and enable you to see in infrared, ultraviolet or even radar wavelengths." Those are lofty claims and Neuralink is some way off from being able to fully restore sight to someone who has lost it, if its ever actually able to do that. It's not the first company or research team to work on vision-restoring implants either. Meanwhile, as TechCrunch points out, it's unlikely that Blindsight or similar tech can help people who have been blind since birth, given that such people have not "developed the biological capacity for seeing through their eyes."This article originally appeared on Engadget at https://www.engadget.com/science/neuralink-says-the-fda-designated-its-blindsight-implant-as-a-breakthrough-device-182343456.html?src=rss


Category: Marketing and Advertising

 

Latest from this category

06.11The Top Workplace Tools Creating Friction and Lost Time [Infographic]
06.11How SMB Marketers Can Turn AI Hype Into Reality With Voice AI
06.11Why Do Large Language Models (LLMs) Love Press Releases?
06.11Seoul transforms subway stations into convenient hubs for the citys runners
05.11How Will AI Impact Marketing and Ad Agency Headcount?
05.11Implementing ABM? Why a Customer Advisory Board Should Be Step One
05.11Montreal doctors can now write patients a prescription for a symphony concert
04.11Software Buying Experiences Online: What Buyers Want From Sellers
Marketing and Advertising »

All news

07.11ITV in talks to sell television business to Sky
07.11How leaders can admit they were wrong
07.11Four ways emotional intelligence helps us navigate turbulent times
07.11Friday Watch
07.11Texas sues Roblox for 'putting paedophiles and profits' over safety
07.11Trump hosts Central Asian leaders as US eyes sources for rare earth metals
07.11Pine labs rakes in money, but profitability a concern
07.11Adani Enterprises to spread Rs 25,000-cr rights issue over 4 tranches
More »
Privacy policy . Copyright . Contact form .